Toll Free: 1-888-928-9744

CIMAB S.A. - Product Pipeline Review - 2014

Published: Oct, 2014 | Pages: 35 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

CIMAB S.A. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'CIMAB S.A. - Product Pipeline Review - 2014', provides an overview of the CIMAB S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of CIMAB S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of CIMAB S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of CIMAB S.A.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the CIMAB S.A.'s pipeline products

Reasons to buy

- Evaluate CIMAB S.A.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of CIMAB S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the CIMAB S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of CIMAB S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of CIMAB S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of CIMAB S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
CIMAB S.A. Snapshot 5
CIMAB S.A. Overview 5
Key Information 5
Key Facts 5
CIMAB S.A. - Research and Development Overview 6
Key Therapeutic Areas 6
CIMAB S.A. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
CIMAB S.A. - Pipeline Products Glance 13
CIMAB S.A. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
CIMAB S.A. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
CIMAB S.A. - Drug Profiles 17
CIMAvax-EGF Peptide Vaccine 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
epoetin alfa 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Monoclonal Antibody to Inhibit CD20 for Non-Hodgkin Lymphoma and Rheumatoid Arthritis 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Vaccine for Epithelial Cancer 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
14-F7 MAb 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Monoclonal Antibody to Inhibit HER2 for Breast Cancer 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Monoclonal Antibody to Inhibit TNF Alpha for Crohns Disease and Rheumatoid Arthritis 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Monoclonal Antibody to Inhibit VEGF for Cancer 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Pegylated Recombinant Human Erythropoietin Alpha 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Recombinant Protein to Agonize IL-2 for Cancer 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Vaccine for Atherosclerosis 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Vaccine for Cancer 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CIMAB S.A. - Pipeline Analysis 29
CIMAB S.A. - Pipeline Products by Target 29
CIMAB S.A. - Pipeline Products by Route of Administration 30
CIMAB S.A. - Pipeline Products by Molecule Type 31
CIMAB S.A. - Pipeline Products by Mechanism of Action 32
CIMAB S.A. - Locations And Subsidiaries 33
Head Office 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35
List of Tables
CIMAB S.A., Key Information 5
CIMAB S.A., Key Facts 5
CIMAB S.A. - Pipeline by Indication, 2014 8
CIMAB S.A. - Pipeline by Stage of Development, 2014 9
CIMAB S.A. - Monotherapy Products in Pipeline, 2014 10
CIMAB S.A. - Partnered Products in Pipeline, 2014 11
CIMAB S.A. - Partnered Products/ Combination Treatment Modalities, 2014 12
CIMAB S.A. - Phase II, 2014 13
CIMAB S.A. - Phase I, 2014 14
CIMAB S.A. - Preclinical, 2014 15
CIMAB S.A. - Discovery, 2014 16
CIMAB S.A. - Pipeline by Target, 2014 29
CIMAB S.A. - Pipeline by Route of Administration, 2014 30
CIMAB S.A. - Pipeline by Molecule Type, 2014 31
CIMAB S.A. - Pipeline Products by Mechanism of Action, 2014 32 



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify